7.3 C
New York
HomeTop Global NewsHealthcareWhy Pfizer's stumble in the obesity market is a boon for Eli...

Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly


Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market.



Source link

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here